Fred Marin is a French entrepreneur since more than 15 years, in med tech, API development and manufacturing, as well as drug development.
In 2011, he co-founded gmp-orphan SA (“GMPO”), in which Advent LS invested in, and led the company until 2016. More recently, Fred has co-founded OP2 Drugs SAS (“OP2”) with a renowned family office on board, which firstly develops a breakthrough drug in myocardial infarction and heart failure in the US.
He has developed a strong expertise in the registration strategy of repositioning molecules, co-chaired the Repositioning group at the IRDIRC (International Rare Diseases Research Consortium), and is lecturing at business shows or EMA workshops on that topic.
In the 90’s, Fred held various national and international positions in blue chip pharma companies (Roche, Novartis, Schering, etc.), from basic research to marketing and sales, in various therapeutic fields (AIDS, AMD, oncology, etc.).
Fred is PharmD, graduated mainly in molecular immunology, health economy and marketing.